VBL Therapeutics (Nasdaq: VBLT) is developing targeted therapies for immune-inflammatory diseases. VBL’s lead immunology product candidate VB-601 is a targeted antibody for immune-inflammatory applications expected to enter Phase 1 this year that has shown disease-modifying activity across multiple preclinical models including multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease.
Location: Israel, Center District, Modiin-Maccabim-Reut
Member count: 11-50
Total raised: $16.91578M
Founded date: 2000
Investors 1
| Date | Name | Website |
| - | Aurum Vent... | aurum.co.i... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 20.12.2021 | - | $16.91578M | - | - |
Mentions in press and media 3
| Date | Title | Description | Category | Author | Source |
| 09.03.2023 | VBL Therap... | - | - | - | globenewsw... |
| 16.02.2023 | VBL Therap... | - | - | - | globenewsw... |
| 29.06.2016 | The biotec... | There was a time after the 20... | Financing | John Carro... | endpts.com... |